Lyntris Inc. 424B4final IPO prospectus

Executive Summary

Lyntris supplies integrated sensors, hardware and mission software to defense programs, earning revenue through development, production, upgrades and sustainment. FY2025 revenue grew 16.5% to $389M with an $(8.46)M net loss; H1 2026 growth accelerated to 34.6%, but early-stage program costs, accelerated stock-based compensation and interest widened the loss to $(13.0)M. The $298M IPO at $17.50 implies a $2.03B market capitalization, or 5.22× FY2025 revenue, with buyers receiving 14.7% of outstanding shares; two-thirds of shares sold are secondary. Investors are buying embedded defense-program positions and expanding backlog, but the valuation requires profitable contract execution, while company proceeds principally repay lenders rather than fund expansion.

The Offering

• Size and implied valuation: 17.0M shares at $17.50 raise $298M gross, comprising $100M primary and $198M secondary. Based on 115,949,384 shares outstanding afterward, implied market capitalization is $2.03B, buyers’ stake is 14.7%, and valuation is 5.22× FY2025 revenue. Issuing all 12,790,350 shares reserved for future incentive awards would increase the count to 128,739,734, imply $2.25B capitalization and dilute buyers’ stake to 13.2%; this is potential dilution, not outstanding awards.
• Deal mechanics: Lyntris issues 5,714,286 shares; existing holders sell 11,285,714. A 30-day option covers 2,550,000 additional secondary shares, raising buyers’ stake to 16.9% without increasing outstanding shares. Evercore and Citigroup lead the underwriting; shares are approved for NYSE listing as LYNX.
• Money recipients: Company net proceeds of ≈$69.5M fund ≈$60.0M of revolving-debt repayment, leaving ≈$9.5M for general corporate purposes. Selling holders receive secondary-sale proceeds. The primary raise bears $6.0M of underwriting discounts and ≈$24.5M of offering expenses, sharply reducing cash retained.
• Asset backing: Each $17.50 share is backed by $(1.20) of net tangible assets after the IPO—a $18.70 gap. Existing holders paid $2.05 per share on average. Acquisition-related intangible assets explain why tangible backing is negative despite positive accounting equity.
• Capital bridge: “After IPO” assumes the 7/31/2026 refinancing, primary issuance and planned debt repayment. Cash moves from $29.2M before the IPO → $14.2M after refinancing → $23.7M after the IPO; equity moves $56.9M → $47.2M → $117M. Refinancing creates a $9.69M debt-extinguishment charge; the IPO adds ≈$69.5M to equity.
• Future supply: The company has a 180-day lock-up. Directors, executives and substantially all existing holders release 25% of covered shares at each of 180, 360, 540 and 720 days, subject to exceptions. Trive’s planned distribution represents ≈58% of post-IPO shares, creating substantial staged resale capacity.

Key Financial Highlights

Amounts in $M. Annual and interim results are historical; balance sheets are period-end, before the IPO. After-IPO figures are illustrative, not reported results.

¹ Debt is net of issuance costs and excludes equipment loans. ² Equity less goodwill and identifiable intangible assets; after-IPO calculation holds these assets unchanged. The dilution section deducts additional non-tangible assets, producing different net tangible book value.

• Comparability: Accelint and Vitesse combined under common control on 5/7/2026; historical results retrospectively combine predecessor businesses, not a separately operating Lyntris.
• Profitability divergence: H1 stock-based compensation rose to $15.2M as legacy awards vested at the combination. Adjusted EBITDA excludes this and acquisition, restructuring and other costs; its improvement should not obscure declining GAAP EBITDA.
• Cash-flow mechanism: H1 cash generation benefited from customer advances, other liabilities and noncash compensation. Deferred revenue contributed $17.2M, while unbilled receivables reached $39.5M; collections and payment timing remain decisive.
• Balance-sheet quality: H1 goodwill and identifiable intangibles totaled $247M, exceeding equity and causing negative tangible equity. Interest expense of $16.9M exceeded operating income; refinancing and debt repayment offer relief, not proof of sustainable profitability.

Business Model and Growth Drivers

• Embedded positions: More than 200 active programs and ≈150 customers support diversification; no FY2025 program exceeded 7% of revenue. ≈90% of revenue came from sole- or single-source positions, where proprietary designs and qualification requirements support follow-on work.
• Growth mix: H1 maritime revenue increased 66.0% to $113M, space sensing and resilient communications increased 42.1% to $57.6M, and air and missile defense was broadly flat at $70.7M. Allied demand, domestic maritime programs and expanded space-program scope drove acceleration.
• Revenue visibility: Backlog—management’s estimate of future revenue from awarded contracts—reached $924M, +112% Y/Y, but includes work subject to execution, funding and cancellation uncertainty.
• Strategy: Management targets production increases, refreshes, sustainment, broader customer scope and acquisitions, following 12 acquisitions since 2018. Limited long-term supplier commitments expose execution to component availability and costs.

Governance and Control

• Voting influence: One common class carries one vote per share. Trive owns ≈69% before the IPO and plans to distribute retained shares to partners holding ≈58% afterward; it may retain voting or investment authority for recipients requesting continued management.
• Board protections and conflicts: A staggered board and 66⅔% approval requirements constrain shareholder-led changes. Three directors have Trive affiliations, and corporate-opportunity waivers permit specified affiliates to pursue competing opportunities.
• Incentives and reporting: Directors and executives collectively hold ≈8% after sales and distribution. Lyntris expects $4.7M of phantom-unit payouts after the offering; its emerging-growth-company exemptions include no auditor attestation of financial controls.

Risk Assessment

• Financial controls: Four unremediated weaknesses cover reporting processes, segregation of duties, technology controls and related-party transactions; they could undermine reporting reliability.
• Government dependence: U.S. contracts supplied 93% of H1 revenue, substantially all government-linked, exposing awards and payments to appropriations and procurement changes.
• Contract execution: Fixed-price work, cost-to-complete estimates and supplier constraints can turn backlog growth into overruns rather than profit.
• Debt burden: The new facility had $273M outstanding on 7/31/2026; variable rates and leverage covenants can constrain investment despite IPO repayment.
• Acquisition integration: Twelve acquisitions and $192M of H1 goodwill create integration and impairment exposure.
• Security eligibility: Cybersecurity certification and clearance failures could block new or follow-on defense awards.
• Valuation and supply: A 5.22× revenue valuation requires profitable growth, while staged releases of large existing holdings can pressure pricing.

Investor Actionables

At $17.50, the case requires maritime and space demand to convert into durable earnings and cash. Proceeds principally reduce revolving debt, leaving limited incremental expansion funding.

• Demand conversion: Starting with $924M backlog and maritime growth of 66.0%, track revenue delivery and backlog movements; sustained conversion supports the case, while delays or cancellations weaken it.
• Program economics: Starting with 26.6% H1 gross margin, test management’s production-maturation thesis; improving margins support it, while persistent cost overruns contradict it.
• Debt relief and cash quality: Check the planned $60.0M repayment, subsequent interest expense and operating cash flow; lower interest and repeatable cash generation support the case, while reliance on advances or renewed borrowing weakens it.
• Reporting reliability: Track remediation of all four control weaknesses; completed remediation supports confidence, while recurring deficiencies or corrections undermine the financial evidence.